Scholars Central

Conference abstractPublished 28 Mar 2019

Deep dive in aspects of pharmacovigilance for biologics, bio-similar and vaccines

Authors: Ujwala Vilas Salvi

Nucleon Therapeutics LLP, India

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Because no two biologic medicines are identical, post approval safety monitoring will be critical to detect potential differences in safety signals between a biosimilar, its reference product and other biosimilars. Post approval safety monitoring in the USA uses two signal detection systems: Spontaneous Reporting Systems (SRSs) and Active Surveillance (AS) systems. Both depend on accurate identification of the specific product(s) dispensed or administered to patients, which may be compromised when products from multiple manufacturers share common drug nomenclature or coding. The purpose of this study is to describe the entire process of ICSR and signal detection and automation at our PVG center.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Clinical Trials
  • SubjectPharmaceutical Sciences
  • BylineArticles whose byline prints “Ujwala Vilas Salvi”